Egfr Targeted Nanoparticles
Egfr Targeted Nanoparticles - Related Videos
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
0 Views •
Cited by 28 •
2012
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
08:26
Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
0 Views •
Cited by 20 •
2015
Targeted cell delivery is useful in a variety of biomedical applications. The goal of this protocol is to use superparamagnetic iron oxide nanoparticles (SPION) to label cells and thereby enable magnetic cell targeting approaches for a high degree of control over cell delivery and localization.
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
0 Views •
Cited by 12 •
2015
In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
FAQs
After an EGFR-binding molecule engages the receptor, the nanoparticle may accumulate near the corresponding cell and be taken up through receptor-mediated internalization. This creates a biological route that links recognition at the cell surface with intracellular delivery. In bioengineering, the mechanism matters because it can improve where a payload is localized compared with relying only on nonspecific distribution.
The surface-bound recognition component determines how the particle interacts with EGFR. Designs may use a ligand, antibody, or another affinity molecule, each serving as the connection between the nanoparticle surface and the receptor. Functionalizing the surface with these components is therefore a central engineering step, because receptor binding can guide accumulation and internalization.
Targeted and non-targeted delivery differ primarily in whether receptor recognition is built into the particle design. EGFR targeting adds an affinity-based localization step before or during cellular uptake, whereas a system without that feature lacks this deliberate receptor-directed interaction. The targeted strategy is consequently valuable when EGFR expression is being used as a molecular marker in bioengineering research.
Payload placement influences what the system is designed to deliver. A therapeutic or imaging payload may be attached to the nanoparticle or encapsulated within it, while receptor engagement supplies the targeting event. This pairing allows one platform to connect molecular recognition with drug delivery, imaging, or both, while preserving EGFR’s role as the guiding cellular marker.
Design generally begins by selecting a nanoscale carrier and an EGFR-binding surface component, followed by functionalizing the carrier and incorporating the chosen therapeutic or imaging payload. The resulting construct is then considered in relation to receptor binding, possible internalization, and payload localization. This workflow keeps material design, affinity recognition, and intended biological function connected.
In tumor-focused research, investigators can use these systems when EGFR-expressing cells are the intended molecular target. The particles may support delivery of a therapeutic payload, visualization through an imaging payload, or a combination of both. Their value lies in testing whether receptor-guided localization can make nanoscale treatment or detection more selective within a bioengineering design.
Theranostic designs combine therapeutic and diagnostic functions in one nanoparticle platform. For EGFR-targeted systems, the same receptor-recognition strategy can guide a construct carrying treatment, imaging capability, or both. This arrangement is useful when researchers want to study delivery and visualization together, particularly in investigations involving EGFR-expressing tumors.
From a bioengineering perspective, the approach integrates three design layers: nanoscale material construction, molecular affinity at the particle surface, and receptor biology at the target cell. Evaluating all three helps researchers connect particle architecture with biological behavior. That systems-level view supports development of next-generation diagnostic, therapeutic, and combined theranostic platforms rather than treating delivery as a materials problem alone.